Aptose Biosciences Inc. (NASDAQ:APTO) Sees Large Decrease in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 192,700 shares, a decrease of 6.4% from the September 30th total of 205,900 shares. Based on an average trading volume of 535,500 shares, the short-interest ratio is presently 0.4 days. Approximately 1.3% of the shares of the stock are short sold.

Aptose Biosciences Stock Performance

Shares of APTO stock opened at $0.39 on Thursday. Aptose Biosciences has a twelve month low of $0.33 and a twelve month high of $3.32. The company’s 50-day moving average price is $0.39 and its 200-day moving average price is $0.71. The stock has a market cap of $7.06 million, a price-to-earnings ratio of -0.06 and a beta of 1.26.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.15.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 26.62% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Aptose Biosciences in a research note on Monday. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Aptose Biosciences has an average rating of “Moderate Buy” and a consensus price target of $9.00.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.